title: Identification of a novel p190-derived breakpoint Peptide suitable for Peptide vaccine therapeutic approach in ph+ acute lymphoblastic leukemia patients.
abstract: Ph+ acute lymphoblastic leukemia (Ph+ ALL) is a high-risk acute leukemia with poor prognosis, in which the specific t(9;22)(q34;q11) translocation results in a chimeric bcr-abl (e1a2 breakpoint) and in a 190 KD protein (p190) with constitutive tyrosine kinase activity. The advent of first- and second-generation tyrosine kinase inhibitors (TKIs) improved the short-term outcome of Ph+ ALL patients not eligible for allo-SCT; yet disease recurrence is almost inevitable. Peptides derived from p190-breakpoint area are leukemia-specific antigens that may mediate an antitumor response toward p190+ leukemia cells. We identified one peptide named p190-13 able to induce in vitro peptide-specific CD4+ T cell proliferation in Ph+ ALL patients in complete remission during TKIs. Thus this peptide appears a good candidate for developing an immune target vaccine strategy possibly synergizing with TKIs for remission maintenance.
authors.affiliation: Department of Hematology, University of Siena, 53100 Siena, Italy.
authors.forename: Micaela
authors.initials: M
authors.lastname: Ippoliti
authors.forename: Marzia
authors.initials: M
authors.lastname: Defina
authors.forename: Antonella
authors.initials: A
authors.lastname: Gozzini
authors.forename: Claudia
authors.initials: C
authors.lastname: Baratè
authors.forename: Lara
authors.initials: L
authors.lastname: Aprile
authors.forename: Alice
authors.initials: A
authors.lastname: Pietrini
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.forename: Donatella
authors.initials: D
authors.lastname: Raspadori
authors.forename: Francesco
authors.initials: F
authors.lastname: Lauria
authors.forename: Monica
authors.initials: M
authors.lastname: Bocchia